Literature DB >> 15229250

Structural abnormalities in the brains of human subjects who use methamphetamine.

Paul M Thompson1, Kiralee M Hayashi, Sara L Simon, Jennifer A Geaga, Michael S Hong, Yihong Sui, Jessica Y Lee, Arthur W Toga, Walter Ling, Edythe D London.   

Abstract

We visualize, for the first time, the profile of structural deficits in the human brain associated with chronic methamphetamine (MA) abuse. Studies of human subjects who have used MA chronically have revealed deficits in dopaminergic and serotonergic systems and cerebral metabolic abnormalities. Using magnetic resonance imaging (MRI) and new computational brain-mapping techniques, we determined the pattern of structural brain alterations associated with chronic MA abuse in human subjects and related these deficits to cognitive impairment. We used high-resolution MRI and surface-based computational image analyses to map regional abnormalities in the cortex, hippocampus, white matter, and ventricles in 22 human subjects who used MA and 21 age-matched, healthy controls. Cortical maps revealed severe gray-matter deficits in the cingulate, limbic, and paralimbic cortices of MA abusers (averaging 11.3% below control; p < 0.05). On average, MA abusers had 7.8% smaller hippocampal volumes than control subjects (p < 0.01; left, p = 0.01; right, p < 0.05) and significant white-matter hypertrophy (7.0%; p < 0.01). Hippocampal deficits were mapped and correlated with memory performance on a word-recall test (p < 0.05). MRI-based maps suggest that chronic methamphetamine abuse causes a selective pattern of cerebral deterioration that contributes to impaired memory performance. MA may selectively damage the medial temporal lobe and, consistent with metabolic studies, the cingulate-limbic cortex, inducing neuroadaptation, neuropil reduction, or cell death. Prominent white-matter hypertrophy may result from altered myelination and adaptive glial changes, including gliosis secondary to neuronal damage. These brain substrates may help account for the symptoms of MA abuse, providing therapeutic targets for drug-induced brain injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15229250      PMCID: PMC6729247          DOI: 10.1523/JNEUROSCI.0713-04.2004

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  272 in total

1.  Effects of ecstasy/polydrug use on memory for associative information.

Authors:  Denis T Gallagher; John E Fisk; Catharine Montgomery; Jeannie Judge; Sarita J Robinson; Paul J Taylor
Journal:  Psychopharmacology (Berl)       Date:  2012-08       Impact factor: 4.530

2.  Differentiating prenatal exposure to methamphetamine and alcohol versus alcohol and not methamphetamine using tensor-based brain morphometry and discriminant analysis.

Authors:  Elizabeth R Sowell; Alex D Leow; Susan Y Bookheimer; Lynne M Smith; Mary J O'Connor; Eric Kan; Carly Rosso; Suzanne Houston; Ivo D Dinov; Paul M Thompson
Journal:  J Neurosci       Date:  2010-03-17       Impact factor: 6.167

3.  Short communication: quantitative proteomic plasma profiling reveals activation of host defense to oxidative stress in chronic SIV and methamphetamine comorbidity.

Authors:  Gurudutt Pendyala; Sunia A Trauger; Gary Siuzdak; Howard S Fox
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-07       Impact factor: 2.205

4.  Synergism between methamphetamine and the neuropeptide substance P on the production of nitric oxide in the striatum of mice.

Authors:  Jing Wang; Jesus A Angulo
Journal:  Brain Res       Date:  2010-11-11       Impact factor: 3.252

5.  Striatum and insula dysfunction during reinforcement learning differentiates abstinent and relapsed methamphetamine-dependent individuals.

Authors:  Jennifer L Stewart; Colm G Connolly; April C May; Susan F Tapert; Marc Wittmann; Martin P Paulus
Journal:  Addiction       Date:  2013-12-15       Impact factor: 6.526

6.  Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls.

Authors:  Jonathan H Morra; Zhuowen Tu; Liana G Apostolova; Amity E Green; Christina Avedissian; Sarah K Madsen; Neelroop Parikshak; Xue Hua; Arthur W Toga; Clifford R Jack; Norbert Schuff; Michael W Weiner; Paul M Thompson
Journal:  Hum Brain Mapp       Date:  2009-09       Impact factor: 5.038

Review 7.  Nucleus accumbens invulnerability to methamphetamine neurotoxicity.

Authors:  Donald M Kuhn; Mariana Angoa-Pérez; David M Thomas
Journal:  ILAR J       Date:  2011

8.  Methamphetamine-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice.

Authors:  J P Q Zhu; W Xu; J A Angulo
Journal:  Neuroscience       Date:  2006-05-02       Impact factor: 3.590

9.  Impact of interacting functional variants in COMT on regional gray matter volume in human brain.

Authors:  Robyn Honea; Beth A Verchinski; Lukas Pezawas; Bhaskar S Kolachana; Joseph H Callicott; Venkata S Mattay; Daniel R Weinberger; Andreas Meyer-Lindenberg
Journal:  Neuroimage       Date:  2008-11-21       Impact factor: 6.556

10.  PET studies of d-methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and ( --)-cocaine.

Authors:  Joanna S Fowler; Carsten Kroll; Richard Ferrieri; David Alexoff; Jean Logan; Stephen L Dewey; Wynne Schiffer; David Schlyer; Pauline Carter; Payton King; Colleen Shea; Youwen Xu; Lisa Muench; Helene Benveniste; Paul Vaska; Nora D Volkow
Journal:  J Nucl Med       Date:  2007-09-14       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.